Acceleron's Sotatercept Receives the US FDA's Breakthrough Therapy Designation for Pulmonary Arterial Hypertension
Shots:
- The US FDA has granted BTD to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH)
- Earlier- the company reported results of P-II PULSAR study that demonstrated sotatercept has the potential to shift the current treatment paradigm and provide benefits to patients with PAH on top of currently available therapies
- Sotatercept is an investigational agent designed to be a selective ligand trap for members of the TGF-beta superfamily to rebalance BMPR-II signaling
Ref: Businesswire | Image: Businesswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
